SLC17A7 and depressive symptom measurement: Prevented the abnormal induction of vGluT1 positive glutamatergic neurons by reducing the level of Ngn2; enhanced the balance between GABAergic and glutamatergic neurons after TBI; improved anxiety, depression‐like behavior, and memory function after TBI